Tin tức & Cập nhật

Chỉ hiển thị Multimedia

Ankylosing spondylitis patients may be at risk of developing dementia

19 Aug 2020

Ankylosing spondylitis (AS) appears to convey about a 20-percent increased risk of developing dementia, according to the results of a systematic review and meta-analysis.

Ankylosing spondylitis patients may be at risk of developing dementia

19 Aug 2020

Selected antidepressants may be bad for bones in older women

12 Aug 2020

Use of antidepressants in older women has been linked to cortical bone and physical function deterioration, effects that are specific to selective serotonin reuptake inhibitors (SSRIs) and serotonin norepinephrine reuptake inhibitors (SNRIs), a study has found.

Selected antidepressants may be bad for bones in older women

12 Aug 2020

Canakinumab exerts lasting effects in colchicine-resistant familial Mediterranean fever

07 Aug 2020

Patients with colchicine-resistant familial Mediterranean fever benefit from long-term treatment with canakinumab, preventing flares and controlling disease activity without increasing adverse events, according to the results of a phase III study.

Canakinumab exerts lasting effects in colchicine-resistant familial Mediterranean fever

07 Aug 2020

Secukinumab gets FDA nod for nr-axSpA

05 Aug 2020 bởi

The US FDA has given secukinumab the greenlight for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA), following its success in the phase III PREVENT trial, the largest ever for a biologic in nr-axSpa.

Secukinumab gets FDA nod for nr-axSpA

05 Aug 2020

Novel biomarkers of disease activity identified in various forms of vasculitis

04 Aug 2020

Several serum biomarkers of disease activity have been recognized in giant cell arteritis (GCA) and eosinophilic granulomatosis with polyangiitis (EGPA), according to a study. Moreover, differences in biomarker levels between diseases are more evident than those related to disease activity.

Novel biomarkers of disease activity identified in various forms of vasculitis

04 Aug 2020

$Tofacitinib, peficitinib touted as top treatments for refractory RA$

Tofacitinib, peficitinib touted as top treatments for refractory RA

04 Aug 2020 bởi

The Janus kinase inhibitors tofacitinib 10 mg and peficitinib 150 mg prove to be the most effective regimens in the treatment of patients with refractory rheumatoid arthritis (RA) receiving methotrexate (MTX), without increasing the risk of serious adverse events, according to the results of a network meta-analysis.

Tofacitinib, peficitinib touted as top treatments for refractory RA

04 Aug 2020

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

Ankylosing spondylitis patients may be at risk of developing dementia

Ankylosing spondylitis patients may be at risk of developing dementia

Selected antidepressants may be bad for bones in older women

Selected antidepressants may be bad for bones in older women

Canakinumab exerts lasting effects in colchicine-resistant familial Mediterranean fever

Canakinumab exerts lasting effects in colchicine-resistant familial Mediterranean fever

Secukinumab gets FDA nod for nr-axSpA

Secukinumab gets FDA nod for nr-axSpA

Novel biomarkers of disease activity identified in various forms of vasculitis

Novel biomarkers of disease activity identified in various forms of vasculitis

Tofacitinib, peficitinib touted as top treatments for refractory RA

Tofacitinib, peficitinib touted as top treatments for refractory RA